Finance

Lists
EDIT:NASDAQ
Editas Medicine Inc
$2.17
+1.40%
(+0.030) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EDIT...
Open
$2.14
High
$2.21
Low
$2.01
Mkt. cap
334.92M
Avg. vol.
2.42M
Volume
2.79M
52-wk high
$3.94
52-wk low
$1.66
EPS
-$0.62
Beta
2.09
Shares outstanding
154.34M
No. of employees
87
Open
$2.14
High
$2.21
Low
$2.01
Mkt. cap
334.92M
Avg. vol.
2.42M
Volume
2.79M
52-wk high
$3.94
52-wk low
$1.66
EPS
-$0.62
Beta
2.09
Shares outstanding
154.34M
No. of employees
87
News stories
From web sources and news partners
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company that is developing therapies for rare diseases using CRISPR gene editing technology. Editas Medicine headquarters is located in Cambridge, Massachusetts with additional facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc
CEO-
Employees87
FoundedNov 2013
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteeditasmedicine.com
Analyst ratings
Based on 5 analysts giving stock ratings to EDIT in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for EDIT in the last 3 months.
Highest
Current $2.17
$6.00 (+176.50%)
Average
$5.20 (+139.63%)
Lowest
$4.00 (+84.33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$5.00
+130.4%
11/10/2026
Luca Issi
RBC Capital
Hold
Maintained
$4.00
+84.3%
11/09/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$6.00
+176.5%
11/09/2026
Debjit Chattopadhyay
Guggenheim
Buy
Upgraded
$5.00
+130.4%
09/23/2026
Rick Bienkowski
Ladenburg Thalmann & Co.
Buy
Initiated
$6.00
+176.5%
08/18/2026
Alec Stranahan
Bank of America Securities
Sell
Reiterated
-
-
08/07/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
08/05/2026
Boris Peaker
JonesTrading
Buy
Maintained
$8.00
+268.7%
08/05/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$15.00
+591.2%
05/27/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
$4.00
+84.3%
05/05/2026
Soumit Roy
JonesTrading
Buy
Maintained
$8.00
+268.7%
04/06/2026
Joon Lee
Truist Financial
Hold
Maintained
-
-
03/17/2026
Brian Cheng
J.P. Morgan
Sell
Maintained
-
-
03/13/2026
William Maughan
Clear Street
Buy
Maintained
$4.60
+112%
03/10/2026
Last report
Nov 9, 2026
Fiscal period
Q3 2026
-$0.15 / -$0.21
+27.23%beat
Revenue / Est. (USD)
10.36M / 4.53M
+128.58%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
24.74M
2.83M
11.89M
10.36M
Cost of goods sold
27.40M
17.60M
20.18M
21.17M
Cost of revenue
27.40M
17.60M
20.18M
21.17M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.35M
10.23M
11.60M
13.48M
Operating expense
11.35M
10.23M
11.60M
13.48M
Total operating expenses
38.76M
27.83M
31.78M
34.65M
Operating income
-14.02M
-25.00M
-19.89M
-24.28M
Other non operating income
2.18M
-113.00K
17.00K
-1.00K
EBT including unusual items
-5.62M
-24.98M
-18.23M
-23.39M
EBT excluding unusual items
-9.69M
-24.98M
-19.57M
-23.39M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-5.62M
-24.98M
-18.23M
-23.39M
Net profit margin
-22.72%
-882.44%
-153.32%
-225.69%
Earnings per share
-0.06
-0.26
-0.15
-0.15
Interest and investment income
2.14M
1.21M
1.37M
1.97M
Interest expense
-
-1.07M
-1.06M
-1.08M
Net interest expenses
2.14M
134.00K
307.00K
890.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.21M
-24.52M
-19.48M
-23.90M
Gain or loss from assets sale
34.00K
-
111.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps